z-logo
Premium
Accelerating the Development of Personalized Cancer Immunotherapy by Integrating Molecular Patients’ Profiles with Dynamic Mathematical Models
Author(s) -
Agur Zvia,
Elishmereni Moran,
Foryś Urszula,
Kogan Yuri
Publication year - 2020
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1942
Subject(s) - precision medicine , personalized medicine , personalization , computer science , profiling (computer programming) , disease , data science , immunotherapy , medicine , medical physics , cancer , bioinformatics , computational biology , biology , pathology , world wide web , operating system
We review the evolution, achievements, and limitations of the current paradigm shift in medicine, from the “one‐size‐fits‐all” model to “Precision Medicine.” Precision, or personalized, medicine—tailoring the medical treatment to the personal characteristics of each patient—engages advanced statistical methods to evaluate the relationships between static patient profiling (e.g., genomic and proteomic), and a simple clinically motivated output (e.g., yes/no responder). Today, precision medicine technologies that have facilitated groundbreaking advances in oncology, notably in cancer immunotherapy, are approaching the limits of their potential, mainly due to the scarcity of methods for integrating genomic, proteomic and clinical patient information. A different approach to treatment personalization involves methodologies focusing on the dynamic interactions in the patient‐disease‐drug system, as portrayed in mathematical modeling. Achievements of this scientific approach, in the form of algorithms for predicting personal disease dynamics in individual patients under immunotherapeutic drugs, are reviewed as well. The contribution of the dynamic approaches to precision medicine is limited, at present, due to insufficient applicability and validation. Yet, the time is ripe for amalgamating together these two approaches, for maximizing their joint potential to personalize and improve cancer immunotherapy. We suggest the roadmap toward achieving this goal, technologically, and urge clinicians, pharmacologists, and computational biologists to join forces along the pharmaco‐clinical track of this development.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here